BR112021022431A2 - Moduladores de molécula pequena de metabolismo bacteriano intestinal do ácido biliar - Google Patents
Moduladores de molécula pequena de metabolismo bacteriano intestinal do ácido biliarInfo
- Publication number
- BR112021022431A2 BR112021022431A2 BR112021022431A BR112021022431A BR112021022431A2 BR 112021022431 A2 BR112021022431 A2 BR 112021022431A2 BR 112021022431 A BR112021022431 A BR 112021022431A BR 112021022431 A BR112021022431 A BR 112021022431A BR 112021022431 A2 BR112021022431 A2 BR 112021022431A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- hepatitis
- cancer
- liver
- small molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0027—Azides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846457P | 2019-05-10 | 2019-05-10 | |
| US202062962048P | 2020-01-16 | 2020-01-16 | |
| PCT/US2020/032016 WO2020231776A1 (en) | 2019-05-10 | 2020-05-08 | Small molecule modulators of gut bacterial bile acid metabolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022431A2 true BR112021022431A2 (pt) | 2022-05-24 |
Family
ID=73289482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022431A BR112021022431A2 (pt) | 2019-05-10 | 2020-05-08 | Moduladores de molécula pequena de metabolismo bacteriano intestinal do ácido biliar |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12577273B2 (https=) |
| EP (1) | EP3965748A4 (https=) |
| JP (2) | JP7769176B2 (https=) |
| KR (2) | KR20250171471A (https=) |
| CN (2) | CN120757601A (https=) |
| AU (1) | AU2020274319B2 (https=) |
| BR (1) | BR112021022431A2 (https=) |
| CA (1) | CA3137308A1 (https=) |
| WO (1) | WO2020231776A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186329B2 (en) | 2018-08-23 | 2025-01-07 | President And Fellows Of Harvard College | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes |
| EP3890745B1 (en) | 2018-12-04 | 2025-11-19 | President and Fellows of Harvard College | Synthetic derivatives of cholic acid 7-sulfate and uses thereof |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| IT202200008861A1 (it) * | 2022-05-03 | 2023-11-03 | Chemelectiva S R L | Processo per la preparazione di derivati dell’acido colico. |
| CN115337312B (zh) * | 2022-08-19 | 2025-06-03 | 金熊药业(珠海横琴)有限公司 | 胆酸复合物及其制备方法和应用 |
| CN117801047B (zh) * | 2023-01-19 | 2024-12-20 | 北京华睿鼎信科技有限公司 | 神经甾体衍生物及其用途 |
| CN118021751A (zh) * | 2024-01-15 | 2024-05-14 | 中国人民解放军总医院第五医学中心 | 一种免疫调节的口服微球、制备方法及应用 |
| US20250299939A1 (en) * | 2024-03-25 | 2025-09-25 | Thermo Finnigan Llc | Calibration of an Image Current-based Mass Analyzer Included in a Mass Spectrometer |
| WO2025235593A1 (en) * | 2024-05-09 | 2025-11-13 | The Regents Of The University Of California | Treatment for obstructive sleep apnea-associated atherosclerosis |
| CN119565571B (zh) * | 2024-10-17 | 2025-11-21 | 湖北省食品质量安全监督检验研究院(湖北食品、保健食品、化妆品质量安全检测中心) | 一种不溶性吸附除氟复合材料颗粒及其制备方法、应用和除氟包 |
| CN119950519B (zh) * | 2025-01-07 | 2025-11-21 | 山东省海洋科学研究院(青岛国家海洋科学研究中心) | 奥贝胆酸在对虾急性肝胰腺坏死病防治中的应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1360354A (en) | 1972-01-20 | 1974-07-17 | Union International Co Ltd | Chenodeoxycholic acid |
| JPS5826360B2 (ja) | 1974-08-23 | 1983-06-02 | エ−ザイ カブシキガイシヤ | グリコケノデオキシコ−ルサンノ セイホウ |
| IT1221734B (it) | 1983-02-24 | 1990-07-12 | Schiena Michele Giuseppe Di | Ursodesossicolico solfato acido sale sodico |
| US5210272A (en) | 1990-02-16 | 1993-05-11 | Prototek, Inc. | Process for forming a fluoromethyl ketone |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| NZ245504A (en) | 1991-12-20 | 1995-08-28 | Hoechst Ag | Bile acid derivatives containing an ethylenically unsaturated grouping |
| IT1255450B (it) | 1992-06-30 | 1995-10-31 | Montefarmaco Spa | Uso di acidi biliari come agenti antivirali |
| EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
| IT1270853B (it) | 1993-05-20 | 1997-05-13 | Sanofi Elf | Procedimento per la preparazione di derivati taurocolanici |
| EP0717631B1 (en) | 1993-09-09 | 2003-07-09 | Lorus Therapeutics Inc. | Immunomodulating compositions from bile |
| US5695738A (en) | 1995-06-15 | 1997-12-09 | Glycomed Incorporated | Steroidal C-glycosides |
| US5763435A (en) | 1995-11-21 | 1998-06-09 | Children's Hospital Medical Center | Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders |
| CA2206047A1 (en) | 1997-05-23 | 1998-11-23 | Romeo Rang (Deceased) | Immunomodulating compositions for the treatment of viral disorders |
| DE19849722A1 (de) | 1998-10-28 | 2000-05-04 | Aventis Pharma Gmbh | Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| CN1187364C (zh) | 1999-04-30 | 2005-02-02 | 亚其发展公司 | 类固醇衍生物 |
| DE19941764A1 (de) | 1999-09-02 | 2001-03-15 | Aventis Pharma Gmbh | Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente |
| SK3862002A3 (en) | 1999-09-22 | 2003-01-09 | Aventis Pharma Gmbh | 4-Benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use |
| US6451355B1 (en) | 2000-07-17 | 2002-09-17 | Howard M. Reisner | Composition to treat diabetes |
| ITTO20020102A1 (it) | 2002-02-06 | 2003-08-06 | Abc Ist Biolog Chem Spa | Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili. |
| ITMI20030822A1 (it) | 2003-04-18 | 2004-10-19 | Erregierre Spa | Processo per la preparazione dell'acido ursodesossicolico |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| CA2608052A1 (en) | 2005-05-10 | 2006-11-16 | Laboratoires Fournier S.A. | Novel use of liver x receptor agonists |
| US9295677B2 (en) | 2008-02-26 | 2016-03-29 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
| CA2758023A1 (en) | 2008-04-09 | 2009-10-15 | Cornell University | Commensal bacteria as signal mediators within a mammalian host |
| CA2744697C (en) | 2008-11-26 | 2016-06-21 | Satiogen Pharmaceuticals, Inc. | Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes |
| WO2012151252A2 (en) | 2011-05-02 | 2012-11-08 | Biokier, Inc. | Composition and method for treatment of diabetes |
| IT1393095B1 (it) | 2009-02-19 | 2012-04-11 | Prodotti Chimici Alimentari | Processo per la sintesi del sale disodico dell'acido ursodesossicolico 3,7-disolfato. |
| US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| EP2470553B1 (en) | 2009-08-25 | 2024-06-19 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
| CA2859965A1 (en) | 2011-12-21 | 2013-06-27 | Ardelyx, Inc. | Non-systemic tgr5 agonists |
| WO2013113680A1 (en) | 2012-02-03 | 2013-08-08 | Aarhus Universitet | Radiolabeled bile acids and bile acid derivatives |
| US20140206657A1 (en) | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
| US9580459B2 (en) | 2013-04-26 | 2017-02-28 | Metselex, Inc. | Water-soluble ursodeoxycholic acid prodrugs |
| US10538550B2 (en) | 2014-11-19 | 2020-01-21 | NZP UK Limited | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators |
| US20190125745A1 (en) | 2014-12-17 | 2019-05-02 | Rgenix, Inc. | Treatment and diagnosis of cancer |
| AR103260A1 (es) * | 2014-12-23 | 2017-04-26 | 4D Pharma Res Ltd | Modulación inmunitaria |
| TW201704251A (zh) * | 2015-04-29 | 2017-02-01 | 正大天晴藥業集團股份有限公司 | 鵝去氧膽酸衍生物 |
| EP3310801B1 (en) | 2015-06-19 | 2021-04-07 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| TWI618714B (zh) * | 2015-08-27 | 2018-03-21 | 中央研究院 | 涎酸轉移酶抑制劑及其用途 |
| CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| WO2017142895A1 (en) * | 2016-02-15 | 2017-08-24 | Regents Of The University Of Minnesota | Compositions and methods for treating clostridium associated diseases |
| US20170233431A1 (en) | 2016-02-17 | 2017-08-17 | City Of Hope | Bile acid derivatives and methods for synthesis and use |
| RU2665685C1 (ru) | 2017-09-18 | 2018-09-04 | Общество с ограниченной ответственностью "МДК Медика" | Способ получения алкиламмонийных солей алкилсерных кислот |
| JP2020536566A (ja) * | 2017-10-13 | 2020-12-17 | バッテル メモリアル インスティチュート | 胆汁酸塩ヒドロラーゼプローブならびにその製造方法および使用方法 |
| US20210122780A1 (en) | 2018-03-29 | 2021-04-29 | Metselex, Inc. | Compositions for the prevention and treatment of parkinson's disease |
| US12186329B2 (en) | 2018-08-23 | 2025-01-07 | President And Fellows Of Harvard College | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes |
| EP3890745B1 (en) | 2018-12-04 | 2025-11-19 | President and Fellows of Harvard College | Synthetic derivatives of cholic acid 7-sulfate and uses thereof |
| WO2021226447A1 (en) | 2020-05-08 | 2021-11-11 | President And Fellows Of Harvard College | Methods for inducing bile acid sulfotransferase sult2a for treating metabolic disorders |
-
2020
- 2020-05-08 KR KR1020257039741A patent/KR20250171471A/ko active Pending
- 2020-05-08 WO PCT/US2020/032016 patent/WO2020231776A1/en not_active Ceased
- 2020-05-08 BR BR112021022431A patent/BR112021022431A2/pt unknown
- 2020-05-08 CN CN202510563299.XA patent/CN120757601A/zh active Pending
- 2020-05-08 CN CN202080050183.1A patent/CN114641280B/zh active Active
- 2020-05-08 CA CA3137308A patent/CA3137308A1/en active Pending
- 2020-05-08 JP JP2021567062A patent/JP7769176B2/ja active Active
- 2020-05-08 EP EP20805532.7A patent/EP3965748A4/en active Pending
- 2020-05-08 KR KR1020217040058A patent/KR102893599B1/ko active Active
- 2020-05-08 AU AU2020274319A patent/AU2020274319B2/en active Active
- 2020-05-08 US US17/610,037 patent/US12577273B2/en active Active
-
2025
- 2025-08-28 JP JP2025141993A patent/JP2026000925A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220204548A1 (en) | 2022-06-30 |
| EP3965748A4 (en) | 2023-02-01 |
| CN114641280A (zh) | 2022-06-17 |
| WO2020231776A8 (en) | 2021-05-14 |
| US12577273B2 (en) | 2026-03-17 |
| WO2020231776A1 (en) | 2020-11-19 |
| CN120757601A (zh) | 2025-10-10 |
| CN114641280B (zh) | 2025-05-27 |
| KR20250171471A (ko) | 2025-12-08 |
| JP2022533069A (ja) | 2022-07-21 |
| AU2020274319A1 (en) | 2021-12-02 |
| EP3965748A1 (en) | 2022-03-16 |
| CA3137308A1 (en) | 2020-11-19 |
| KR102893599B1 (ko) | 2025-12-01 |
| JP2026000925A (ja) | 2026-01-06 |
| KR20220007112A (ko) | 2022-01-18 |
| AU2020274319B2 (en) | 2026-02-12 |
| JP7769176B2 (ja) | 2025-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022431A2 (pt) | Moduladores de molécula pequena de metabolismo bacteriano intestinal do ácido biliar | |
| Maslennikov et al. | Gut microbiota and bacterial translocation in the pathogenesis of liver fibrosis | |
| Xu et al. | Hyperuricemia is associated with impaired intestinal permeability in mice | |
| Ciorba et al. | Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner | |
| Park et al. | Recent advances in autoimmune pancreatitis | |
| MX2025002978A (es) | Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad | |
| Jubelin et al. | Modulation of enterohaemorrhagic Escherichia coli survival and virulence in the human gastrointestinal tract | |
| Kiouptsi et al. | Contribution of the commensal microbiota to atherosclerosis and arterial thrombosis | |
| Zheng et al. | The microbiome in autoimmune liver diseases: metagenomic and metabolomic changes | |
| Nicoletti et al. | Biliary tract microbiota: a new kid on the block of liver diseases? | |
| Alvarez et al. | Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala | |
| Lee et al. | Lactobacillus plantarum and Bifidobacterium longum alleviate liver injury and fibrosis in mice by regulating NF-κB and AMPK signaling | |
| Pirola et al. | Circulating MicroRNA-122 signature in nonalcoholic fatty liver disease and cardiovascular disease: a new endocrine system in metabolic syndrome | |
| Gottlieb et al. | Nonalcoholic-fatty-liver-disease and nonalcoholic steatohepatitis: successful development of pharmacological treatment will depend on translational research | |
| MX2023005550A (es) | Inhibidores de diclorofenol hsd17b13 y usos de los mismos. | |
| Mateos-Muñoz et al. | Enterohepatic Helicobacter other than Helicobacter pylori | |
| van der Wulp et al. | Laxative treatment with polyethylene glycol decreases microbial primary bile salt dehydroxylation and lipid metabolism in the intestine of rats | |
| Merola et al. | Non‐alcoholic fatty liver disease following liver transplantation: a clinical review | |
| Sharma et al. | Isomaltooligosaccharides utilization and genomic characterization of human infant anti-inflammatory Bifidobacterium longum and Bifidobacterium breve strains | |
| Ganesan et al. | A critical review of microbiome-derived metabolic functions and translational research in liver diseases | |
| Meacci et al. | Microbial Landscapes of the Gut–Biliary Axis: Implications for Benign and Malignant Biliary Tract Diseases | |
| Romeo et al. | The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications | |
| Liu et al. | Intratumoral microbiota: an emerging force in diagnosing and treating hepatocellular carcinoma | |
| Nie et al. | Gut Microbiota: Implications in Pathogenesis and Potential Therapeutic Target in Primary Biliary Cholangitis | |
| Arai et al. | Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025012723-0 PROTOCOLO 870250051762 EM 20/06/2025 13:05. |